Oncology

Latest News

The investigators found that patients with SCLC and cachexia were more likely to have problems with treatment. | Image credit: appledesign - stock.adobe.com
Cachexia Worsens Prognosis in Older Patients With Advanced SCLC

July 9th 2025

Older patients with small cell lung cancer and significant weight loss were more likely to experience dose interruptions than patients with cachexia.

Insurance gaps | Image Credit: iQoncept-stock.adobe.com
Insurance Gaps Threaten Cancer Treatment Success

July 7th 2025

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski
Decline in SCLC Incidence Expected to Accelerate Through 2050

June 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com
Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com
Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

June 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
July 10th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 10th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Educating Patients About Risk of Febrile Neutropenia Associated With Strong Chemotherapy
October 31st 2017

Educating Patients About Risk of Febrile Neutropenia Associated With Strong Chemotherapy

AJMC Staff
Strong chemotherapy may be part of the treatment plan for patients diagnosed with cancer, but it also comes with risks. A new campaign will empower patients with cancer to better understand and navigate risks such as febrile neutropenia that are associated with strong chemotherapy.
70-GS Influences Physician Treatment Guidance for Patients With Early Breast Cancer
October 31st 2017

70-GS Influences Physician Treatment Guidance for Patients With Early Breast Cancer

Jaime Rosenberg
Results of the 70-gene signature assay strongly influence physician's treatment recomendations for patients with early breast cancer who were classified as intermediate risk by the 21-gene assay.
Site Logo
October 30th 2017

Data Challenges Under the Oncology Care Model

Darcie Hurteau
An overview of factors that make the Oncology Care Model performance period data challenging to navigate and use.
Global Cancer Burden in Young Adults Differs From That in Other Age Groups
October 30th 2017

Global Cancer Burden in Young Adults Differs From That in Other Age Groups

Jaime Rosenberg
A new study found that the global cancer burden in young adults differs from that in younger and older age groups and was more common in women.
ARROW Trial: Multiple Myeloma Patients Have Longer PFS With Kyprolis Once-Weekly Regimen
October 29th 2017

ARROW Trial: Multiple Myeloma Patients Have Longer PFS With Kyprolis Once-Weekly Regimen

Alison Rodriguez
Results of the Phase 3 ARROW trial revealed that patiehts with refractory multiple myeloma can live up to 3.6 months longer, without their disease worsening, when Kyprolis (carfilzomib) is administered once-weekly at the 70 mg/m2 dose with dexamethasone rather than Kyprolis administered twice-weekly at the 27 mg/m2 dose with dexamethasone, according to Amgen.
Study Finds Association Between PARPis Treatment and Severe Hematologic Toxicities
October 28th 2017

Study Finds Association Between PARPis Treatment and Severe Hematologic Toxicities

Alison Rodriguez
Study Finds Need for Standardization of Immune Checkpoint Inhibitor Assays in NSCLC
October 28th 2017

Study Finds Need for Standardization of Immune Checkpoint Inhibitor Assays in NSCLC

Alison Rodriguez
Site Logo
October 27th 2017

Expanding Options for Individualized Treatment of Advanced NSCLC

Christina Mattina
James R. Jett, MD, gave an overview of the advances in diagnosis and treatment of non–small cell lung cancer (NSCLC) during a session at the National Association of Managed Care Physicians Fall Managed Care Forum 2017.
Childhood Cancer Survivors Face Job Lock to Keep Insurance Coverage
October 27th 2017

Childhood Cancer Survivors Face Job Lock to Keep Insurance Coverage

Alison Rodriguez
Many of survivors of childhood cancer who are now within the prime age for labor force participation are reluctant to make changes in their employment because of access to health insurance, and therefore, job lock is common among this population.
Site Logo
October 26th 2017

Survey: Americans Have High Concerns About Cancer, Low Awareness of Risk Factors

Kelly Davio
Results of the first annual National Cancer Opinion Survey, established by the American Society of Clinical Oncology (ASCO), show that the majority of Americans are unaware of several key risk factors for cancer, and that a minority are taking active steps to reduce their personal risk.
Site Logo
October 25th 2017

Stakeholders Weigh-in on Payment Reform in Cancer Care

Surabhi Dangi-Garimella, PhD
Tuple Health, a healthcare technology startup, interviewed some of the stakeholders participating in value-based care delivery and OCM, to gain their perspective of the state of cancer care and healthcare reform. The results were presented at the Community Oncology Alliance Payer Exchange Summit on Oncology Payment Reform.
Site Logo
October 25th 2017

The Commercial Payer OCM Experience: Year 1

Surabhi Dangi-Garimella, PhD
Representatives from 3 payers who partnered with providers on the Oncology Care Model (OCM) took the stage at Community Oncology Alliance (COA)’s Payer Exchange Summit on Oncology Payment Reform to outline their experience with OCM and how it has differed from other care models.
Terrill Jordan: Education and Data Are Key for OCM Success
October 25th 2017

Terrill Jordan: Education and Data Are Key for OCM Success

Education is key to succeed in the Oncology Care Model, but presenting data in a simple format for clinicians to use is also critical, said Terrill Jordan, CEO, of Regional Cancer Care Associates.
Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia
October 25th 2017

Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia

Alison Rodriguez
Researchers developed additional guidance for using granulocyte colony-stimulating factors to optimize pegfilgrastim use in clinical practices for patients at risk of chemotherapy-induced febrile neutropenia.
Physicians Need Clearer Metrics Before Taking on 2-Sided Risk
October 25th 2017

Physicians Need Clearer Metrics Before Taking on 2-Sided Risk

Before physicians will be more willing to take on 2-sided risk, there needs to be clearer metrics that the physicians know will be achievable, said Sarah Cevallos, chief revenue cycle officer at Florida Cancer Specialists.
Site Logo
October 25th 2017

The Option Value of Innovative Treatments for Non–Small Cell Lung Cancer and Renal Cell Carcinoma

Julia Thornton Snider, PhD Katharine Batt, MD, MSc Yanyu Wu, PhD Mahlet Gizaw Tebeka, MS Seth Seabury, PhD
Option value is the benefit a therapy provides patients by enabling them to survive to the next innovation.
Site Logo
October 24th 2017

Dr Lucio Gordan: How Practices and Payers Work Together to Implement OCM

The implementation of the Oncology Care Model has brought profound culture changes to how oncologists take care of patients and how they operate practices, explained Lucio Gordan, MD, of Florida Cancer Specialists.
Site Logo
October 24th 2017

Will 2-Sided Risk Be a Reality in OCM?

Kelly Davio
With the Oncology Care Model now in its second year, 3 representatives discussed learnings and how the program can change, as well as incentivizing physicians to accept 2-sided risk, the ability to engage additional payers, and the future of oncology bundle payments.
Site Logo
October 24th 2017

How Has the OCM Evolved? Year 1 Provider Updates

Surabhi Dangi-Garimella, PhD
Participants from 2 oncology community practices—an oncologist–administrator combination—shared their experience with implementing the Oncology Care Model (OCM) with attendees at the Community Oncology Alliance’s Payer Exchange Summit on Oncology Payment Reform, held October 23-24, in Tysons Corner, Virginia.
Site Logo
October 24th 2017

Study: Prophylactic Up-Front Locoregional Surgery Has No Survival Advantage

Jaime Rosenberg
The study found that prophylactic locoregional surgery (LRS) for asymptomatic patients with small intestinal neuroendocrine tumors (SI-NETs) provided no survival advantage compared with delayed LRS.
Site Logo
October 23rd 2017

Increased Insurance Coverage Seen Under the ACA for Patients With Cancer

Jaime Rosenberg
A new study has found that uninsurance rates declined the most in patients with distant disease and with lung and bronchial cancer. Hispanic patients also saw a large decrease in uninsurance rates.
Podcast: This Week in Managed Care - Bipartisan ACA Deal and Other Health News
October 21st 2017

Podcast: This Week in Managed Care - Bipartisan ACA Deal and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This Week in Managed Care: October 20, 2017
October 20th 2017

This Week in Managed Care: October 20, 2017

This week, the top managed care news included the bipartisan deal to stabilize the Affordable Care Act's insurance markets; coverage from the Academy of Managed Care Pharmacy 2017 Nexus; and a plan to reduce clinician burnout at the computer.
Site Logo
October 19th 2017

Kite Pharma's CAR T-Cell Treatment Approved, Cheaper Than Tisagenlecleucel

Surabhi Dangi-Garimella, PhD
Axicabtagene ciloleucel (Yescarta) has been approved to treat adult patients with diffuse large B-cell lymphoma who have not responded to or who have relapsed after at least 2 other kinds of treatment.
Site Logo
October 18th 2017

PD-1 Inhibitor Doubled Survival in Treatment-Naive Patients With mNSCLC

Surabhi Dangi-Garimella, PhD
The 2-year follow up results from the Keynote-024 trial were presented at the 18th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Yokohama, Japan.
Site Logo
October 18th 2017

Increasing Levels of CD8+ TILs Prolong Survival in High-Grade Serous Ovarian Cancer

Jaime Rosenberg
There is a relationship between CD8+ tumor infiltrating lymphocytes (TILs) and high-grade serous ovarian carcinoma (HGSOC) survival, according to a new study published in JAMA Oncology.
Site Logo
October 17th 2017

PBMs: Their Role, the Problems, and How Practices Can Work With Them

Ray Bailey, RPh Ricky Newton, CPA
Site Logo
October 17th 2017

Positive Quality Interventions: An Innovative Platform for Oncology Practice Collaboration

Joshua Nubla, PharmD Neal Dave, PharmD Michael Reff, RPh, MBA
An in-depth look into a nationwide collaborative initiative to standardize and improve oncology dispensing practices for the benefit of patient/provider education, adherence, and overall care.
Site Logo
October 17th 2017

Looking Ahead at the Specialty Drug Pipeline After an Active Year of Approvals

Christina Mattina
Aimee Tharaldson, PharmD, of Express Scripts kicked off the Academy of Managed Care Pharmacy (AMCP) 2017 Nexus, held October 16-19 in Dallas, Texas, with a presentation on the pipeline of specialty pharmaceuticals in development.
Site Logo
October 17th 2017

UK Patients With Head and Neck Cancer Will Soon Have Access to Nivolumab

Jaime Rosenberg
The immunotherapy drug, made by Bristol-Myers Squibb, is recommended for use within the Cancer Drug Fund.
<1
...
646566676869707172
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo